|
Volumn 42, Issue 3, 2004, Pages 1386-1387
|
Quality Control Guidelines for MIC Susceptibility Testing of Omiganan Pentahydrochloride (MBI 226), a Novel Antimicrobial Peptide [5]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMPHOTERICIN B;
ANTIBIOTIC AGENT;
FLUCYTOSINE;
LEVOFLOXACIN;
MBI 226;
OMIGANAN;
UNCLASSIFIED DRUG;
VANCOMYCIN;
AMINO ACID SEQUENCE;
ANTIBIOTIC PROPHYLAXIS;
ANTIBIOTIC SENSITIVITY;
CANDIDA KRUSEI;
CATHETER INFECTION;
CELL DEATH;
CELL MEMBRANE;
CLINICAL TRIAL;
DRUG MECHANISM;
ENTEROCOCCUS FAECALIS;
ESCHERICHIA COLI;
HUMAN;
LETTER;
MINIMUM INHIBITORY CONCENTRATION;
NONHUMAN;
PEPTIDE SYNTHESIS;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PSEUDOMONAS AERUGINOSA;
QUALITY CONTROL;
STAPHYLOCOCCUS AUREUS;
STREPTOCOCCUS PNEUMONIAE;
ANTIMICROBIAL CATIONIC PEPTIDES;
BACTERIA;
GUIDELINES;
MICROBIAL SENSITIVITY TESTS;
QUALITY ASSURANCE, HEALTH CARE;
REPRODUCIBILITY OF RESULTS;
YEASTS;
CANDIDA;
ENTEROCOCCUS;
ENTEROCOCCUS FAECALIS;
ESCHERICHIA COLI;
ISSATCHENKIA ORIENTALIS;
PSEUDOMONAS;
PSEUDOMONAS AERUGINOSA;
STAPHYLOCOCCUS;
STAPHYLOCOCCUS AUREUS;
STREPTOCOCCUS;
STREPTOCOCCUS PNEUMONIAE;
|
EID: 1542513769
PISSN: 00951137
EISSN: None
Source Type: Journal
DOI: 10.1128/JCM.42.3.1386-1387.2004 Document Type: Letter |
Times cited : (15)
|
References (6)
|